CDKN2A and cancer: For example, the TAD chr9:21240000-24400999, which is prognostic for LGG, comprises the prognostic pan-cancer gene CDKN2A. LGG patients with CNVs in this TAD (n = 96) exhibited lower survival than patients with no CNVs in this TAD (n = 414; p < 0.0001, log-rank test), and at least part of the predictive power of the TADs was not associated with the gene: Namely, the survival of the patients with CNVs affecting CDKN2A (n = 87) did not differ from that of the patients with CNVs in the TAD that did not affect CDKN2A (n = 9; log-rank test; see Figure 4E,F).